Dr. Aklank Jain

Contact Info
Dr. Aklank Jain
Dr. Aklank Jain

 Professor,  Recipient of Ramanujan Fellowship, 

 Department of Zoology

 School of Basic Sciences

Qualification

M.Sc. -  Jamia Hamdard, New Delhi

Ph.D. -  Jamia Millia Islamia, New Delhi and All India Institute of Medical Sciences, New Delhi

Post-Doctoral Research -  1.  Oncology Institute of Southern Switzerland (01-12-2005 to 01-03-2007)

                                              2.  MD Anderson Cancer Center, Houston, Texas, USA  (01-06-2007 to 01-02-2011)

                                              3.  The University of Texas at Austin, Texas, USA  (01-03-2011 to 01-06-2012)  

Experience
Teaching Experience : 9+ years
 
Research Experience : 17+ years
 
Administrative Experience: 6+ years
 

 

Research Area

Cancer is the second most leading cause of mortality and morbidity worldwide. Cancer can originate in any part of the body and is an important issue that has an impact on the health of all human communities and races. In regard to this, our lab performed a hospital-based survey study in the Malwa region of Punjab to determine the precise statistics of the cancer burden in our locality (Rana et al. 2021). We discovered that the three most common cancers are non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), and triple-negative breast cancer (TNBC) and they required immediate attention. As a result, our group helped build a panel of potential lncRNAs as an early-stage diagnostic biomarker for non-small cell lung carcinoma and tentatively in order to increase the odds of survival for cancer patients. We then filed a patent in the Indian Jurisdiction (Provisional number # 202111035477).

TNBC is a very hostile type of cancer and has high rates of incidence and recurrence globally. In this regard, our team investigated lncRNA ZFAS1 as a liquid biopsy-based diagnostic biomarker for TNBC. We found that ZFAS1 acts as a tumor suppressor in breast cancer malignancy by inhibiting the expression levels of the cyclin-dependent kinase (CDK) inhibitors p21 (CDKN1A) and p27 (CDKN1B). We found that downregulation of ZFAS1 led to decreased protein levels of epithelial markers like E-cadherin, Claudin-1, and Zo-1, and increased protein levels of mesenchymal markers like Slug and ZEB1, hence decreasing epithelial-to-mesenchymal transition. Moreover, we reported that ZFAS1 expression significantly increased STAT3 and phosphorylated STAT3 protein levels in TNBC cells (Sharma et al. 2021).

More recently, our team also found two lncRNAs, namely, LINC00324 and LOC100507053 that are essential for the emergence and progression of ESCC. Both of these lncRNAs is linked to the poor survival and prognosis of ESCC patients. LINC00324 and LOC100507053 were significantly upregulated and downregulated respectively in ESCC patients. We found that the silencing of LINC00324 modulates cell proliferation markers like p21, p27, c-Myc, and Cyclin D1 and epithelial-to-mesenchymal transition markers, slug, snail, ZEB1, vimentin, ZO-1, and E-cadherin in ESCC. Furthermore, LINC00324 negatively regulated miR-493-5p and interacted with the MAPK1 molecule via the MAPK signaling pathway in ESCC patients. Therefore, it was established that LINC00324 significantly reduces ESCC cell proliferation and metastasis by sponging miR-493-5p. Hence, they can be used as a diagnostic potential candidate marker for ESCC screening (Sharma et al. 2022).

Research Interests

Identification of non-coding RNA based biomarkers for cancers

Research Grants/Projects

S. No

Title of Project

Funding Agency

Year

1.

Identification of circulating microRNAs as novel noninvasive biomarkers for early detection of lung cancer

ICMR, India

2017-2020

2.

Novel Aspects of Molecular Pathogenesis of Hereditary Breast Cancer, Indo-Russia Project

DST, India

2018-2020
Research Collaboration

 

All India Institute of Medical Sciences, Bathinda

NN Petrov National Medical Research Center of Oncology

Publications
  1. Goyal F, Chattopadhyay A, Navik U, Jain A, Reddy PH, Bhatti GK, et al. Advancing Cancer Immunotherapy: The Potential of mRNA Vaccines as a Promising Therapeutic Approach. Advanced Therapeutics.(2024);7(2):2300255. https://doi.org/https://doi.org/10.1002/adtp.202300255. Impact factor = 4.6
  2. Mohanta A, Kumar RR, Singh RK, Mandal S, Yadav R, Khatkar R, Sharma U, Uttam V, Rana MK, Rana AP, Jain A The emerging role of miR-320a in lung cancer: a comprehensive review. Biomarkers in Medicine. 2023 Dec 14.  Impact factor = 2.2
  3. Uttam V, Rana MK, Sharma U, Singh K, & Jain A. Circulating long non-coding RNA EWSAT1 acts as a liquid biopsy marker for esophageal squamous cell carcinoma: A pilot study. Non-coding RNA research. 2023; 9(1), 1–11. Impact factor = 5
  4. Hussain A, Kumar A, Uttam V, Sharma U, Sak K, Saini RV, Saini AK, Haque S, Tuli HS, Jain A, Sethi G. Application of curcumin nanoformulations to target folic acid receptor in cancer: Recent trends and advances. Environmental Research. 2023 Sep; 233:116476. Impact factor = 8.3
  5. Madaan P, Sharma U, Tyagi N, Brar B K, Bansal S, Kushwaha H R, Kapoor H S, Jain A, & Jain M. A panel of blood-based circulatory miRNAs with diagnostic potential in patients with psoriasis. Frontiers in medicine. 2023 Aug 28; 10, 1207993. Impact factor = 3.9
  6. Sharma U, Kaur Rana M, Singh K, Jain A. LINC00324 promotes cell proliferation and metastasis of esophageal squamous cell carcinoma through sponging miR-493-5p via MAPK signaling pathway. Biochemical Pharmacology. 2023 Jan;207:115372. Impact factor = 6.1
  7. Kumar P, Kumawat RK, Uttam V, Behera A, Rani M, Singh N, Barwal TS, Sharma U, Jain A. The imminent role of microRNAs in salivary adenoid cystic carcinoma. Translational Oncology. 2023 Jan; 27:101573. Impact factor =4.803
  8. Tuli HS, Garg VK, Bhushan S, Uttam V, Sharma U, Jain A, Sak K, Yadav V, Lorenzo JM, Dhama K, Behl T, Sethi G. Natural flavonoids exhibit potent anticancer activity by targeting microRNAs in cancer: A signature step hinting towards clinical perfection. Translational Oncology. 2023 Jan; 27:101596. Impact factor= 4.803
  9. Sharma U, Tuli HS, Uttam V, Choudhary R, Sharma B, Sharma U, Prakash H, Jain A. Role of Hedgehog and Hippo signaling pathways in cancer: A special focus on non-coding RNAs. Pharmacological Research. 2022 Dec; 186:106523. Impact factor = 10.33
  10. Tuli HS, Sak K, Garg, VK, Kumar A, Adhikary, S, Kaur, G, Parashar, NC, Parashar, G, Mukherjee, T K, Sharma U, Jain A, Mohapatra R K, Dhama K, Kumar M, Singh T. Ampelopsin targets in cellular processes of cancer: Recent trends and advances. Toxicology Reports. 2022 July; 9:1614-1623
  11. Barwal TS, Singh N, Sharma U, Bazala S, Rani M, Behera A, …. Jain A. miR-590-5p: A double-edged sword in the oncogenesis process. Cancer treatment and research communications. 2022;32:100593. Impact factor = 1.57
  12. Roy RK, Yadav R, Sharma U, Kaushal Wasson M, Sharma A, Tanwar P, Jain A, Prakash H. Impact of non‐coding RNAs on cancer directed immune therapies: Now then and forever. International Journal of Cancer. 2022 Apr 30. Impact factor = 7.39
  13. Tuli HS, Sak K, Iqubal A, Garg VK, Varol M, Sharma U, Chauhan A, Yerer MB, Dhama K, Jain M, Jain A. STAT signaling as a target for intervention: from cancer inflammation and angiogenesis to non-coding RNAs modulation. Molecular Biology Reports. 2022 Apr 26:1-3. Impact factor = 2.31
  14. Sharma U, Barwal TS, Murmu M, Acharya V, Pant N, Dey D, Vivek, Gautam A, Bazala S, Singh I, Azzouz F, Jain A. Clinical potential of long non-coding RNA LINC01133 as a promising biomarker and therapeutic target in cancers. Biomarkers in Medicine. 2022 Apr;16(5):349-69. Impact factor = 2.49
  15. Rana MK, Rana APS, Sharma U, Barwal TS, Jain A. Evolution of Frozen Section in Carcinoma Breast: Systematic Review. International journal of breast cancer. 2022;2022:4958580.
  16. Sharma, U., Murmu, M., Barwal, T.S., Tuli, H.S., Jain, M., Prakash, H., Kaceli, T., Jain, A. and Bishayee, A., 2022. A Pleiotropic Role of Long Non-Coding RNAs in the Modulation of Wnt/β-Catenin and PI3K/Akt/mTOR Signaling Pathways in Esophageal Squamous Cell Carcinoma: Implication in Chemotherapeutic Drug Response. Current Oncology, 29(4), pp.2326-2349. Impact factor = 3.10
  17. Roy RK, Yadav R, Jain A, Tripathi V, Jain M, Singh S, Prakash H. Yin and yang of immunological memory in controlling infections: Overriding self defence mechanisms. International Reviews of Immunology. 2022 Feb 21;41(2):240-52. Impact factor = 3.48
  18. Lypaczewski P, Thakur L, Jain A, Kumari S, Paulini K, Matlashewski G, Jain M. An intraspecies Leishmania donovani hybrid from the Indian subcontinent is associated with an atypical phenotype of cutaneous disease. Iscience. 2022 Feb 18;25(2):103802. Impact factor = 6.10
  19. Tuli HS, Sak K, Adhikary S, Kaur G, Aggarwal D, Kaur J, Kumar M, Parashar NC, Parashar G, Sharma U, Jain A. Galangin: A metabolite that suppresses anti-neoplastic activities through modulation of oncogenic targets. Experimental Biology and Medicine. 2022 Feb;247(4):345-59. Impact factor = 4.08
  20. Barwal TS, Sharma U, Rana MK, Bazala S, Singh I, Murmu M, Kapoor HS, Thakur S, Jain M, Jain A. A diagnostic and prognostic value of blood-based circulating long non-coding rnas in thyroid, pancreatic and ovarian cancer. Critical Reviews in Oncology/Hematology. 2022 Jan 13:103598. Impact factor = 6.312
  21. Kundu N, Sharma T, Kaur S, Singh M, Kumar V, Sharma U, Jain A, Shankaraswamy J, Miyoshi D, Saxena S. Significant structural change in human c-Myc promoter G-quadruplex upon peptide binding in potassium. RSC advances. 2022;12(13):7594-604. Impact factor = 3.36
  22. Sharma U, Barwal TS, Khandelwal A, Rana MK, Rana AP, Singh K, Jain A. Circulating Long Non-Coding RNAs LINC00324 and LOC100507053 as Potential Liquid Biopsy Markers for Esophageal Squamous Cell Carcinoma: A Pilot Study. Frontiers in oncology. 2022;12. Impact factor = 6.24
  23. Roy RK, Sharma U, Wasson MK, Jain A, Hassan MI, Prakash H. Macrophage Activation Syndrome and COVID 19: Impact of MAPK Driven Immune-Epigenetic Programming by SARS-Cov-2. Frontiers in immunology. 2021;12. Impact factor = 7.56
  24. Thakur L, Madaan P, Jain A, Shankar V, Negi AK, Chauhan SB, Sundar S, Singh OP, Jain M. An insight into systemic immune response in Leishmania donovani mediated Atypical CL in the new endemic state of Himachal Pradesh, India. Frontiers in immunology.2021;5179. Impact factor = 7.56
  25. Bangroo A, Malhotra A, Sharma U, Jain A, Kaur A. Biosynthesis of Zinc Oxide Nanoparticles Using Catharanthus roseus Leaves and Their Therapeutic Response in Breast Cancer (MDA-MB-231) Cells. Nutrition and cancer. 2021:1-7. Impact factor = 2.90
  26. Rana MK, Barwal TS, Sharma U, Bansal R, Singh K, Rana APS, Jain A, Khera U. Current Trends of Carcinoma: Experience of a Tertiary Care Cancer Center in North India. Cureus. 2021;13(6):e15788. Impact factor = 1.15
  27. Chairmadurai A, Jain SK, Jain A, Prakash H. Rapid Arc-SBRT: Non-invasive immune adjuvant for advanced stage Non-Small Cell Lung Carcinoma. Anti-cancer agents in medicinal chemistry. 2021. Imapct factor = 2.80
  28. Aggarwal V, Tuli HS, Varol M, Tuorkey M, Sak K, Parashar NC, Barwal TS, Sharma U, Iqubal A, Parashar G, Jain A. NOTCH signaling: Journey of an evolutionarily conserved pathway in driving tumor progression and its modulation as a therapeutic target. Critical reviews in oncology/hematology. 2021;164:103403. Impact factor = 6.31
  29. Barwal TS, Sharma U, Bazala S, Singh I, Jain M, Prakash H, Shekhar S, Sandberg EN, Bishayee A, Jain A. MicroRNAs and Long Non-coding RNAs as Novel Therapeutic Targets in Estrogen Receptor-Positive Breast and Ovarian Cancers. International journal of molecular sciences. 2021;22(8). Impact factor = 5.92
  30. Roy RK, Yadav R, Jain A, Tripathi V, Jain M, Singh S, Prakash H. Yin and yang of immunological memory in controlling infections: Overriding self defence mechanisms. International reviews of immunology. 2021:1-12. Impact factor = 5.31
  31. Khandelwal A, Sharma U, Barwal TS, Seam RK, Gupta M, Rana MK, Vasquez KM, Jain A. Circulating miR-320a Acts as a Tumor Suppressor and Prognostic Factor in Non-small Cell Lung Cancer. Frontiers in oncology. 2021;11:645475. Impact factor = 6.25
  32. Sharma U, Barwal TS, Khandelwal A, Malhotra A, Rana MK, Singh Rana AP, Imyanitov EN, Vasquez KM, Jain A. LncRNA ZFAS1 inhibits triple-negative breast cancer by targeting STAT3. Biochimie. 2021;182:99-107. Imapct factor = 4.07
  33. Toor D, Jain A, Kalhan S, Manocha H, Sharma VK, Jain P, Tripathi V, Prakash H. Tempering Macrophage Plasticity for Controlling SARS-CoV-2 Infection for Managing COVID-19 Disease. Frontiers in pharmacology. 2020;11:570698. Impact factor = 5.81
  34. Prakash H, Upadhyay D, Bandapalli OR, Jain A, Kleuser B. Host sphingolipids: Perspective immune adjuvant for controlling SARS-CoV-2 infection for managing COVID-19 disease. Prostaglandins & other lipid mediators. 2021;152:106504. Impact factor = 3.07
  35. Tuli HS, Mittal S, Aggarwal D, Parashar G, Parashar NC, Upadhyay SK, Barwal TS, Jain A, Kaur G, Savla R, Sak K, Kumar M, Varol M, Iqubal A, Sharma AK. Path of Silibinin from diet to medicine: A dietary polyphenolic flavonoid having potential anti-cancer therapeutic significance. Seminars in cancer biology. 2021;73:196-218. Impact factor = 15.70
  36. Nadella V, Garg M, Kapoor S, Barwal TS, Jain A, Prakash H. Emerging neo adjuvants for harnessing therapeutic potential of M1 tumor associated macrophages (TAM) against solid tumors: Enusage of plasticity. Annals of translational medicine. 2020;8(16):1029. Impact factor = 3.93
  37. Sharma U, Barwal TS, Acharya V, Singh K, Rana MK, Singh SK, Prakash H, Bishayee A, Jain A. Long Non-Coding RNAs as Strategic Molecules to Augment the Radiation Therapy in Esophageal Squamous Cell Carcinoma. International journal of molecular sciences. 2020;21(18). Impact factor = 5.92
  38. Thakur L, Kushwaha HR, Negi A, Jain A, Jain M. Leptomonas seymouri Co-infection in Cutaneous Leishmaniasis Cases Caused by Leishmania donovani From Himachal Pradesh, India. Frontiers in cellular and infection microbiology. 2020;10:345. Impact factor = 5.29
  39. Thakur L, Singh KK, Kushwaha HR, Sharma SK, Shankar V, Negi A, Verma G, Kumari S, Jain A, Jain M. Leishmania donovani Infection with Atypical Cutaneous Manifestations, Himachal Pradesh, India, 2014-2018. Emerging infectious diseases. 2020;26(8):1864-9. Impact factor = 6.88
  40. Barwal TS, Sharma U, Vasquez KM, Prakash H, Jain A. A panel of circulating long non-coding RNAs as liquid biopsy biomarkers for breast and cervical cancers. Biochimie. 2020;176:62-70. Imapct factor = 4.07
  41. Sharma U, Barwal TS, Malhotra A, Pant N, Vivek, Dey D, Gautam A, Tuli HS, Vasquez KM, Jain A. Long non-coding RNA TINCR as potential biomarker and therapeutic target for cancer. Life sciences. 2020;257:118035. Impact factor = 5.03
  42. Aggarwal V, Tuli HS, Tania M, Srivastava S, Ritzer EE, Pandey A, Aggarwal D, Barwal TS, Jain A, Kaur G, Sak K, Varol M, Bishayee A. Molecular mechanisms of action of epigallocatechin gallate in cancer: Recent trends and advancement. Seminars in cancer biology. 2020. Impact factor = 15.70
  43. Sharma U, Barwal TS, Acharya V, Tamang S, Vasquez KM, Jain A. Cancer Susceptibility Candidate 9 (CASC9): A Novel Targetable Long Non-coding RNA in Cancer Treatment. Translational oncology. 2020;13(8):100774. Impact factor = 4.24
  44. Tuli HS, Tuorkey MJ, Thakral F, Sak K, Kumar M, Sharma AK, Sharma U, Jain A, Aggarwal V, Bishayee A. Molecular Mechanisms of Action of Genistein in Cancer: Recent Advances. Frontiers in pharmacology. 2019;10:1336. Impact factor = 5.81
  45. Aggarwal V, Tuli HS, Varol A, Thakral F, Yerer MB, Sak K, Varol M, Jain A, Khan MA, Sethi G. Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements. Biomolecules. 2019;9(11). Impact factor = 4.87
  46. Tamang S, Acharya V, Roy D, Sharma R, Aryaa A, Sharma U, Khandelwal A, Prakash H, Vasquez KM, Jain A. SNHG12: An LncRNA as a Potential Therapeutic Target and Biomarker for Human Cancer. Frontiers in oncology. 2019;9:901. Impact factor = 6.25
  47. Khandelwal A, Seam RK, Gupta M, Rana MK, Prakash H, Vasquez KM, Jain A. Circulating microRNA-590-5p functions as a liquid biopsy marker in non-small cell lung cancer. Cancer science. 2020;111(3):826-39. Impact factor = 6.71
  48. Aggarwal V, Kashyap D, Sak K, Tuli HS, Jain A, Chaudhary A, Garg VK, Sethi G, Yerer MB. Molecular Mechanisms of Action of Tocotrienols in Cancer: Recent Trends and Advancements. International journal of molecular sciences. 2019;20(3). Impact factor = 5.92
  49. Malhotra A, Sharma U, Puhan S, Chandra Bandari N, Kharb A, Arifa PP, Thakur L, Prakash H, Vasquez KM, Jain A. Stabilization of miRNAs in esophageal cancer contributes to radioresistance and limits efficacy of therapy. Biochimie. 2019;156:148-57. Imapct factor = 4.07
  50. Thakur L, Singh KK, Shanker V, Negi A, Jain A, Matlashewski G, Jain M. Atypical leishmaniasis: A global perspective with emphasis on the Indian subcontinent. PLoS neglected tropical diseases. 2018;12(9):e0006659. Impact factor = 4.41
  51. Nadella V, Singh S, Jain A, Jain M, Vasquez KM, Sharma A, Tanwar P, Rath GK, Prakash H. Low dose radiation primed iNOS + M1macrophages modulate angiogenic programming of tumor derived endothelium. Molecular carcinogenesis. 2018;57(11):1664-71. Impact factor = 4.78
  52. Jain A, Wang G, Vasquez KM. Corrigendum to "DNA Triple Helices: Biological consequences and therapeutic potential" [Biochimie 90/8 (2008) 1117-1130]. Biochimie. 2018;148:139. Imapct factor = 4.07
  53. Malhotra A, Jain M, Prakash H, Vasquez KM, Jain A. The regulatory roles of long non-coding RNAs in the development of chemoresistance in breast cancer. Oncotarget. 2017;8(66):110671-84. Impact factor = 4.14
  54. Saluja R, Kumar A, Jain M, Goel SK, Jain A. Role of Sphingosine-1-Phosphate in Mast Cell Functions and Asthma and Its Regulation by Non-Coding RNA. Frontiers in immunology. 2017;8:587. Impact factor = 7.56
  55. Khandelwal A, Malhotra A, Jain M, Vasquez KM, Jain A. The emerging role of long non-coding RNA in gallbladder cancer pathogenesis. Biochimie. 2017;132:152-60. Imapct factor = 4.07
  56. Khandelwal A, Bacolla A, Vasquez KM, Jain A. Long non-coding RNA: A new paradigm for lung cancer. Molecular carcinogenesis. 2015;54(11):1235-51. Impact factor = 4.78
  57. Bacolla A, Temiz NA, Yi M, Ivanic J, Cer RZ, Donohue DE, Ball EV, Mudunuri US, Wang G, Jain A, Volfovsky N, Luke BT, Stephens RM, Cooper DN, Collins JR, Vasquez KM. Guanine holes are prominent targets for mutation in cancer and inherited disease. PLoS genetics. 2013;9(9):e1003816. Impact factor = 5.91
  58. Jain A, Bacolla A, Del Mundo IM, Zhao J, Wang G, Vasquez KM. DHX9 helicase is involved in preventing genomic instability induced by alternatively structured DNA in human cells. Nucleic acids research. 2013;41(22):10345-57. Impact factor = 16.97
  59. Bacolla A, Wang G, Jain A, Chuzhanova NA, Cer RZ, Collins JR, Cooper DN, Bohr VA, Vasquez KM. Non-B DNA-forming sequences and WRN deficiency independently increase the frequency of base substitution in human cells. The Journal of biological chemistry. 2011;286(12):10017-26. Impact factor = 5.15
  60. Jain A, Bacolla A, Chakraborty P, Grosse F, Vasquez KM. Human DHX9 helicase unwinds triple-helical DNA structures. Biochemistry. 2010;49(33):6992-9. Impact factor = 3.16
  61. Jain A, Magistri M, Napoli S, Carbone GM, Catapano CV. Mechanisms of triplex DNA-mediated inhibition of transcription initiation in cells. Biochimie. 2010;92(3):317-20. Imapct factor = 4.07
  62. Zhao J, Jain A, Iyer RR, Modrich PL, Vasquez KM. Mismatch repair and nucleotide excision repair proteins cooperate in the recognition of DNA interstrand crosslinks. Nucleic acids research. 2009;37(13):4420-9. Impact factor = 16.97
  63. Jain A, Wang G, Vasquez KM. DNA triple helices: biological consequences and therapeutic potential. Biochimie. 2008;90(8):1117-30. Imapct factor = 4.07
  64. Cangemi R, Mensah A, Albertini V, Jain A, Mello-Grand M, Chiorino G, Catapano CV, Carbone GM. Reduced expression and tumor suppressor function of the ETS transcription factor ESE-3 in prostate cancer. Oncogene. 2008;27(20):2877-85. Impact factor = 9.86
  65. Albertini V, Jain A, Vignati S, Napoli S, Rinaldi A, Kwee I, Nur-e-Alam M, Bergant J, Bertoni F, Carbone GM, Rohr J, Catapano CV. Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy. Nucleic acids research. 2006;34(6):1721-34. Impact factor = 16.97
  66. Jain A, Akanchha S, Rajeswari MR. Stabilization of purine motif DNA triplex by a tetrapeptide from the binding domain of HMGBI protein. Biochimie. 2005;87(8):781-90. Imapct factor = 4.07
  67. Jain A, Ahmad F, Rajeswari MR. Structural studies on DNA triple helix formed by intronic GAA triplet repeat expansion in Friedreich's ataxia. Nucleosides, nucleotides & nucleic acids. 2003;22(5-8):1517-9. Impact factor = 1.38
  68. Jain A, Rajeswari MR. Binding studies on peptide–oligonucleotide complex: intercalation of tryptophan in GC-rich region of c-myc gene. Biochimica et Biophysica Acta (BBA)-General Subjects. 2003;1622(2):73-81. Impact factor = 3.77
  69. Rajeswari MR, Jain A, Sharma A, Singh D, Jagannathan NR, Sharma U, Degaonkar MN. Evaluation of skin tumors by magnetic resonance imaging. Laboratory investigation; a journal of technical methods and pathology. 2003;83(9):1279-83. Impact factor = 5.66
  70. Sharma S, Kaur P, Jain A, Rajeswari MR, Gupta MN. A smart bioconjugate of chymotrypsin. Biomacromolecules. 2003;4(2):330-6. Impact factor = 6.98
  71. Jain A, Rajeswari MR. Preferential binding of quinolones to DNA with alternating G, C / A, T sequences: a spectroscopic study. Journal of biomolecular structure & dynamics. 2002;20(2):291-9. Impact factor = 3.39
  72. Jain A, Rajeswari MR, Ahmed F. Formation and thermodynamic stability of intermolecular (R*R*Y) DNA triplex in GAA/TTC repeats associated with Friedreich’s ataxia. Journal of biomolecular structure & dynamics. 2002;19(4):691-9. Impact factor = 3.39
  73. Rajeswari MR, Jain A. High-mobility-group chromosomal proteins, HMGA1 as potential tumor markers. Current Science. 2002:838-44. Impact factor = 1.10
  74. Rajeswari MR, Singh D, Jain A, Ray R. Elevated levels of high-mobility-group chromosomal proteins, HMGA1, in murine skin carcinoma. Cancer letters. 2001;173(1):93-9. Impact factor = 8.69
Research Guidance

Ph.D. Students: 4

Completed: 3

  1. Akanksha Khandelwal
  2. Lovlesh Thakur
  3. Uttam Sharma 

Ongoing: 1

  1. Vivek (UGC- NFSC JRF)

M.Sc. Students (2020-22): 5 

  1. Pawan Kumar
  2. Medha Rani
  3. Neha 
  4. Alisha Behera
  5. Ram Kumar Kumawat

M.Sc. Students (2021-23): 6       

  1. Rinku
  2. Surojit Mandal
  3. Adrija Mohanta 
  4. Rahul kumar Singh
  5. Rajiv Ranjan Kumar
  6. Ritu Yadav

M.Sc. Students (2022-24): 7

  1. Dewan Chettri
  2. Chinmayee Priyadarsini Dash
  3. Dhruba Sonowal
  4. Prachi Dhaka
  5. Rohit Yadav
  6. Bibhu Prasad Satapathy
  7. Pooja Sheoran
Conference/ Workshops/Seminars Attended
University Level
 
National
 
International

 

Conference/ Workshops/Seminars Organised
University Level
 
National Level
 
International Level

 

Patent Filed/ Published
PATENT FILED : Yes
 
 
PATENT PUBLISHED
Citations

2820